Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

When we examined the added value of the MS result (positive or negative) among only BM MRD-negative cases at the same specific landmark time point, we observed a potentially favorable PFS benefit for patients with concurrent BM MRD negativity and MS negativity but the difference did not reach statistical significance: NGS − /MS − vs NGS − /MS + (HR, 0.14 [0.01-1.58]; P = .06) and MFC − /MS − vs MFC − /MS + (HR, 0.40 [0.13-1.27]; P = .11; supplemental Figure 5 ).

also in 111,027 other papers